初级保健主导的减重干预对2型糖尿病缓解的持久性:DiRECT开放标签集群随机试验2年结果
DiRECT试验评估初级保健主导的体重管理项目对2型糖尿病缓解的2年持久性。干预组在24个月时36%实现糖尿病缓解,11%减重至少15kg,均显著优于对照组,且缓解与持续减重程度相关。
要点
- 维持至少10kg减重者中64%获得缓解。
核心结论
- DiRECT项目在24个月时使超过三分之一的2型糖尿病患者维持缓解。
- 持续缓解与持续减重的程度相关。
研究设计与样本
- 开放标签、集群随机、对照试验,在英国初级保健机构进行。
- 按1:1随机分配至结构化体重管理项目(干预)或指南最佳实践护理(对照),按研究地点和诊所名单规模分层。
- 纳入20-65岁、2型糖尿病病程小于6年、BMI 27-45 kg/m2且未使用胰岛素的个体。
- 意向性治疗人群每组149人,于24个月分析首要结局。
主要发现
- 干预组129名患者中51人(40%)使用抗糖尿病药物,对照组143人中120人(84%)使用。
- 事后分析显示,维持至少10kg减重者(272名有数据者中45人)中29人(64%)实现缓解;干预组149人中36人(24%)维持至少10kg减重。
关键数值与推荐
- 干预包括停用抗糖尿病和抗高血压药物、总饮食替代(825-853 kcal/日配方饮食12-20周)、逐步食物 reintroduction(2-8周)及结构化体重维持支持。
临床怎么用
- 初级保健可实施结构化体重管理项目以实现2型糖尿病缓解。
- 维持减重(如至少10kg)是维持糖尿病缓解的关键。
局限性
- 开放标签设计,参与者和研究人员知晓分组。
- 事后分析基于有数据亚组,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The DiRECT trial assessed remission of type 2 diabetes during a primary care-led weight-management programme. At 1 year, 68 (46%) of 149 intervention participants were in remission and 36 (24%) had achieved at least 15 kg weight loss. The aim of this 2-year analysis is to assess the durability of the intervention effect. METHODS: DiRECT is an open-label, cluster-randomised, controlled trial done at primary care practices in the UK. Practices were randomly assigned (1:1) via a computer-generated list to provide an integrated structured weight-management programme (intervention) or best-practice care in accordance with guidelines (control), with stratification for study site (Tyneside or Scotland) and practice list size (>5700 or ≤5700 people). Allocation was concealed from the study statisticians; participants, carers, and study research assistants were aware of allocation. We recruited individuals aged 20-65 years, with less than 6 years' duration of type 2 diabetes, BMI 27-45 kg/m2, and not receiving insulin between July 25, 2014, and Aug 5, 2016. The intervention consisted of withdrawal of antidiabetes and antihypertensive drugs, total diet replacement (825-853 kcal per day formula diet for 12-20 weeks), stepped food reintroduction (2-8 weeks), and then structured support for weight-loss maintenance. The coprimary outcomes, analysed hierarchically in the intention-to-treat population at 24 months, were weight loss of at least 15 kg, and remission of diabetes, defined as HbA1c less than 6·5% (48 mmol/mol) after withdrawal of antidiabetes drugs at baseline (remission was determined independently at 12 and 24 months). The trial is registered with the ISRCTN registry, number 03267836, and follow-up is ongoing. FINDINGS: The intention-to-treat population consisted of 149 participants per group. At 24 months, 17 (11%) intervention participants and three (2%) control participants had weight loss of at least 15 kg (adjusted odds ratio [aOR] 7·49, 95% CI 2·05 to 27·32; p=0·0023) and 53 (36%) intervention participants and five (3%) control participants had remission of diabetes (aOR 25·82, 8·25 to 80·84; p<0·0001). The adjusted mean difference between the control and intervention groups in change in bodyweight was -5·4 kg (95% CI -6·9 to -4·0; p<0·0001) and in HbA1c was -4·8 mmol/mol (-8·3 to -1·4 [-0·44% (-0·76 to -0·13)]; p=0·0063), despite only 51 (40%) of 129 patients in the intervention group using anti-diabetes medication compared with 120 (84%) of 143 in the control group. In a post-hoc analysis of the whole study population, of those participants who maintained at least 10 kg weight loss (45 of 272 with data), 29 (64%) achieved remission; 36 (24%) of 149 participants in the intervention group maintained at least 10 kg weight loss. Serious adverse events were similar to those reported at 12 months, but were fewer in the intervention group than in the control group in the second year of the study (nine vs 22). INTERPRETATION: The DiRECT programme sustained remissions at 24 months for more than a third of people with type 2 diabetes. Sustained remission was linked to the extent of sustained weight loss. FUNDING: Diabetes UK.
引用
- Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019. PMID: 30852132. doi:10.1016/S2213-8587(19)30068-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。